Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Income Before Tax

Profit after all operating and non-operating items but before income tax.

Dyadic International, Inc.NASDAQ: DYAI

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$1.95M, compared with -$2.03M a year earlier. Trailing-twelve-month income before tax was -$7.29M.

Context

  • Income before tax amounted to 597.6% of revenue in FY2025, up 431.4 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$1.95M or moves back toward the trailing-twelve-month quarterly average of -$1.82M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.95M-24.7% QoQ
Last fiscal yearDec 2025
-$7.36M-26.8% YoY
LTMMar 2026
-$7.29M-25.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.6%——
1 year-26.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(7.36M) USD
Year-over-year change
-26.8%

Income Before Tax vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.1% is the 6th highest of 8, against a peer median of -20.8%.
  • Income before tax amounts to 245.1% of revenue for DYAI, versus a peer median of 345.4%.
DYAI Competitors
Income Before Tax for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYAIDyadic International, Inc.LTM Mar 2026-$7.29M USD-25.1%—245.1%
ATHEAlterity Therapeutics LimitedFY2025-A$12.08M AUD+36.7%—222.1%
RNXTRenovoRx, Inc.LTM Mar 2026-$12.27M USD-20.8%—824.0%
VERUVeru Inc.LTM Mar 2026-$14.44M USD+49.4%——
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$24.25M USD-23.1%——
PYPDPolyPid Ltd.LTM Mar 2026-$33.64M USD-9.2%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$40.92M USD-40.8%——
CELUCelularity Inc.LTM Dec 2025-$91.71M USD-58.4%—345.4%
Peer median (excluding DYAI) —-20.8%—345.4%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.